Search

Your search keyword '"Yorke, Ellen"' showing total 865 results
Start Over Author "Yorke, Ellen"
865 results on '"Yorke, Ellen"'

1. RMSim: Controlled Respiratory Motion Simulation on Static Patient Scans

Author

Lee, Donghoon, Yorke, Ellen, Zarepisheh, Masoud, Nadeem, Saad, and Hu, Yu-Chi

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

This work aims to generate realistic anatomical deformations from static patient scans. Specifically, we present a method to generate these deformations/augmentations via deep learning driven respiratory motion simulation that provides the ground truth for validating deformable image registration (DIR) algorithms and driving more accurate deep learning based DIR. We present a novel 3D Seq2Seq deep learning respiratory motion simulator (RMSim) that learns from 4D-CT images and predicts future breathing phases given a static CT image. The predicted respiratory patterns, represented by time-varying displacement vector fields (DVFs) at different breathing phases, are modulated through auxiliary inputs of 1D breathing traces so that a larger amplitude in the trace results in more significant predicted deformation. Stacked 3D-ConvLSTMs are used to capture the spatial-temporal respiration patterns. Training loss includes a smoothness loss in the DVF and mean-squared error between the predicted and ground truth phase images. A spatial transformer deforms the static CT with the predicted DVF to generate the predicted phase image. 10-phase 4D-CTs of 140 internal patients were used to train and test RMSim. The trained RMSim was then used to augment a public DIR challenge dataset for training VoxelMorph to show the effectiveness of RMSim-generated deformation augmentation. We validated our RMSim output with both private and public benchmark datasets (healthy and cancer patients). The proposed approach can be used for validating DIR algorithms as well as for patient-specific augmentations to improve deep learning DIR algorithms. The code, pretrained models, and augmented DIR validation datasets will be released at https://github.com/nadeemlab/SeqX2Y., Comment: Physics in Medicine & Biology 2023. Last two authors contributed equally

Published
2023
Full Text
View/download PDF

2. Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial

Author

Rimner, Andreas, Gelblum, Daphna Y., Wu, Abraham J., Shepherd, Annemarie F., Mueller, Boris, Zhang, Siyuan, Cuaron, John, Shaverdian, Narek, Flynn, Jessica, Fiasconaro, Megan, Zhang, Zhigang, von Reibnitz, Donata, Li, Henry, McKnight, Dominique, McCune, Megan, Gelb, Emily, Gomez, Daniel R., Simone, Charles B., II, Deasy, Joseph O., Yorke, Ellen D., Ng, Kenneth K., and Chaft, Jamie E.

Published
2024
Full Text
View/download PDF

10. Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer

Author

Constine, Louis S., Olch, Arthur J., Jackson, Andrew, Hua, Chia-Ho, Ronckers, Cecile M., Milano, Michael T., Marcus, Karen J., Yorke, Ellen, Hodgson, David C., Howell, Rebecca M., Hudson, Melissa M., Williams, Jacqueline P., Marples, Brian, C.M. Kremer, Leontien, Marks, Lawrence B., and Bentzen, Søren M.

Published
2024
Full Text
View/download PDF

13. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation

Author

Thor, Maria, Fitzgerald, Kelly, Apte, Aditya, Oh, Jung Hun, Iyer, Aditi, Odiase, Otasowie, Nadeem, Saad, Yorke, Ellen D., Chaft, Jamie, Wu, Abraham J., Offin, Michael, Simone, Charles B., II, Preeshagul, Isabel, Gelblum, Daphna Y., Gomez, Daniel, Deasy, Joseph O., and Rimner, Andreas

Published
2024
Full Text
View/download PDF

15. Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards

Author

Soltys, Scott G, Milano, Michael T, Xue, Jinyu, Tomé, Wolfgang A, Yorke, Ellen, Sheehan, Jason, Ding, George X, Kirkpatrick, John P, Ma, Lijun, Sahgal, Arjun, Solberg, Timothy, Adler, John, Grimm, Jimm, and El Naqa, Issam

Subjects
Rare Diseases, Cancer, Dose Fractionation, Radiation, Humans, Linear Models, Models, Biological, Models, Theoretical, Neurofibromatosis 2, Neuroma, Acoustic, Poisson Distribution, Probability, Radiosurgery, Radiotherapy Dosage, Relative Biological Effectiveness, Time Factors, Treatment Outcome, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe sought to investigate the tumor control probability (TCP) of vestibular schwannomas after single-fraction stereotactic radiosurgery (SRS) or hypofractionated SRS over 2 to 5 fractions (fSRS).Methods and materialsStudies (PubMed indexed from 1993-2017) were eligible for data extraction if they contained dosimetric details of SRS/fSRS correlated with local tumor control. The rate of tumor control at 5 years (or at 3 years if 5-year data were not available) were collated. Poisson modeling estimated the TCP per equivalent dose in 2 Gy per fraction (EQD2) and in 1, 3, and 5 fractions.ResultsData were extracted from 35 publications containing a total of 5162 patients. TCP modeling was limited by the absence of analyzable data of 12 Gy. Using linear-quadratic-based dose conversion, the 3- to 5-year TCP was estimated at 95% at an EQD2 of 25 Gy, corresponding to 1-, 3-, and 5-fraction doses of 13.8 Gy, 19.2 Gy, and 21.5 Gy, respectively. Single-fraction doses of 10 Gy, 11 Gy, 12 Gy, and 13 Gy predicted a TCP of 85.0%, 88.4%, 91.2%, and 93.5%, respectively. For fSRS, 18 Gy in 3 fractions (EQD2 of 23.0 Gy) and 25 Gy in 5 fractions (EQD2 of 30.2 Gy) corresponded to TCP of 93.6% and 97.2%. Overall, the quality of dosimetric reporting was poor; recommended reporting guidelines are presented.ConclusionsWith current typical SRS doses of 12 Gy in 1 fraction, 18 Gy in 3 fractions, and 25 Gy in 5 fractions, 3- to 5-year TCP exceeds 91%. To improve pooled data analyses to optimize treatment outcomes for patients with vestibular schwannoma, future reports of SRS should include complete dosimetric details with well-defined tumor control and toxicity endpoints.

Published
2021

16. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways

Author

Milano, Michael T, Grimm, Jimm, Soltys, Scott G, Yorke, Ellen, Moiseenko, Vitali, Tomé, Wolfgang A, Sahgal, Arjun, Xue, Jinyu, Ma, Lijun, Solberg, Timothy D, Kirkpatrick, John P, Constine, Louis S, Flickinger, John C, Marks, Lawrence B, and El Naqa, Issam

Subjects
Cancer, Rare Diseases, Brain Cancer, Neurosciences, Eye Disease and Disorders of Vision, Brain Disorders, Patient Safety, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Eye, Adenoma, Blindness, Cavernous Sinus, Craniopharyngioma, Humans, Maximum Tolerated Dose, Meningeal Neoplasms, Meningioma, Models, Biological, Models, Theoretical, Optic Chiasm, Optic Nerve, Organs at Risk, Pituitary Neoplasms, Radiation Dose Hypofractionation, Radiation Tolerance, Radiosurgery, Radiotherapy Dosage, Re-Irradiation, Skull Base Neoplasms, Visual Acuity, Visual Fields, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeDosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation.Methods and materialsEligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION).ResultsThirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in

Published
2021

17. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Author

Kong, Feng-Ming Spring, Moiseenko, Vitali, Zhao, Jing, Milano, Michael T, Li, Ling, Rimner, Andreas, Das, Shiva, Li, X Allen, Miften, Moyed, Liao, ZhongXing, Martel, Mary, Bentzen, Soren M, Jackson, Andrew, Grimm, Jimm, Marks, Lawrence B, and Yorke, Ellen

Subjects
Medical and Biological Physics, Biomedical and Clinical Sciences, Clinical Sciences, Physical Sciences, Oncology and Carcinogenesis, Lung, Rare Diseases, Cancer, Lung Cancer, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Respiratory, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Models, Biological, Models, Theoretical, Organs at Risk, Pulmonary Fibrosis, Radiation Pneumonitis, Radiation Tolerance, Radiosurgery, Radiotherapy Dosage, Re-Irradiation, Risk Factors, Tumor Burden, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeStereotactic body radiation therapy (SBRT) has become the standard of care for inoperable early-stage non-small cell lung cancer and is often used for recurrent lung cancer and pulmonary metastases. Radiation-induced lung toxicity (RILT), including radiation pneumonitis and pulmonary fibrosis, is a major concern for which it is important to understand dosimetric and clinical predictors.Methods and materialsThis study was undertaken through the American Association of Physicists in Medicine's Working Group on Biological Effects of Stereotactic Body Radiotherapy. Data from studies of lung SBRT published through the summer of 2016 that provided detailed information about RILT were analyzed.ResultsNinety-seven studies were ultimately considered. Definitions of the risk organ and complication endpoints as well as dose-volume information presented varied among studies. The risk of RILT, including radiation pneumonitis and pulmonary fibrosis, was reported to be associated with the size and location of the tumor. Patients with interstitial lung disease appear to be especially susceptible to severe RILT. A variety of dosimetric parameters were reported to be associated with RILT. There was no apparent threshold "tolerance dose-volume" level. However, most studies noted safe treatment with a rate of symptomatic RILT of

Published
2021

21. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

Author

Rimner, Andreas, Adusumilli, Prasad S., Offin, Michael D., Solomon, Stephen B., Ziv, Etay, Hayes, Sara A., Ginsberg, Michelle S., Sauter, Jennifer L., Gelblum, Daphna Y., Shepherd, Annemarie F., Guttmann, David M., Eichholz, Jordan E., Zhang, Zhigang, Ritter, Erika, Wong, Phillip, Iqbal, Afsheen N., Daly, Robert M., Namakydoust, Azadeh, Li, Henry, McCune, Megan, Gelb, Emily H., Taunk, Neil K., von Reibnitz, Donata, Tyagi, Neelam, Yorke, Ellen D., Rusch, Valerie W., and Zauderer, Marjorie G.

Published
2023
Full Text
View/download PDF

24. A Prospective Study on Deep Inspiration Breath Hold Thoracic Radiation Therapy Guided by Bronchoscopically Implanted Electromagnetic Transponders

Author

Meng, Yuzhong Jeff, primary, Mankuzhy, Nikhil P., additional, Chawla, Mohit, additional, Lee, Robert P., additional, Yorke, Ellen D., additional, Zhang, Zhigang, additional, Gelb, Emily, additional, Lim, Seng Boh, additional, Cuaron, John J., additional, Wu, Abraham J., additional, Simone II, Charles B. Simone, additional, Gelblum, Daphna Y., additional, Lovelock, Dale Michael, additional, Harris, Wendy, additional, and Rimner, Andreas, additional

Published
2024
Full Text
View/download PDF

27. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology

Author

Mayo, Charles S, Moran, Jean M, Bosch, Walter, Xiao, Ying, McNutt, Todd, Popple, Richard, Michalski, Jeff, Feng, Mary, Marks, Lawrence B, Fuller, Clifton D, Yorke, Ellen, Palta, Jatinder, Gabriel, Peter E, Molineu, Andrea, Matuszak, Martha M, Covington, Elizabeth, Masi, Kathryn, Richardson, Susan L, Ritter, Timothy, Morgas, Tomasz, Flampouri, Stella, Santanam, Lakshmi, Moore, Joseph A, Purdie, Thomas G, Miller, Robert C, Hurkmans, Coen, Adams, Judy, Wu, Qing-Rong Jackie, Fox, Colleen J, Siochi, Ramon Alfredo, Brown, Norman L, Verbakel, Wilko, Archambault, Yves, Chmura, Steven J, Dekker, Andre L, Eagle, Don G, Fitzgerald, Thomas J, Hong, Theodore, Kapoor, Rishabh, Lansing, Beth, Jolly, Shruti, Napolitano, Mary E, Percy, James, Rose, Mark S, Siddiqui, Salim, Schadt, Christof, Simon, William E, Straube, William L, St. James, Sara T, Ulin, Kenneth, Yom, Sue S, and Yock, Torunn I

Subjects
Medical and Biological Physics, Biomedical and Clinical Sciences, Clinical Sciences, Physical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Networking and Information Technology R&D (NITRD), Advisory Committees, Clinical Trials as Topic, Humans, Radiation Oncology, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Reference Standards, Societies, Scientific, Software, Terminology as Topic, United States, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

A substantial barrier to the single- and multi-institutional aggregation of data to supporting clinical trials, practice quality improvement efforts, and development of big data analytics resource systems is the lack of standardized nomenclatures for expressing dosimetric data. To address this issue, the American Association of Physicists in Medicine (AAPM) Task Group 263 was charged with providing nomenclature guidelines and values in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing: (1) structure names across image processing and treatment planning system platforms; (2) nomenclature for dosimetric data (eg, dose-volume histogram [DVH]-based metrics); (3) templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards; (4) formalism for nomenclature schema, which can accommodate the addition of other structures defined in the future. A multisociety, multidisciplinary, multinational group of 57 members representing stake holders ranging from large academic centers to community clinics and vendors was assembled, including physicists, physicians, dosimetrists, and vendors. The stakeholder groups represented in the membership included the AAPM, American Society for Radiation Oncology (ASTRO), NRG Oncology, European Society for Radiation Oncology (ESTRO), Radiation Therapy Oncology Group (RTOG), Children's Oncology Group (COG), Integrating Healthcare Enterprise in Radiation Oncology (IHE-RO), and Digital Imaging and Communications in Medicine working group (DICOM WG); A nomenclature system for target and organ at risk volumes and DVH nomenclature was developed and piloted to demonstrate viability across a range of clinics and within the framework of clinical trials. The final report was approved by AAPM in October 2017. The approval process included review by 8 AAPM committees, with additional review by ASTRO, European Society for Radiation Oncology (ESTRO), and American Association of Medical Dosimetrists (AAMD). This Executive Summary of the report highlights the key recommendations for clinical practice, research, and trials.

Published
2018

39. Radiation Dose‐Volume Effects for Liver SBRT

Author

Miften, Moyed, Vinogradskiy, Yevgeniy, Moiseenko, Vitali, Grimm, Jimm, Yorke, Ellen, Jackson, Andrew, Tomé, Wolfgang A., Ten Haken, Randall K., Ohri, Nitin, Méndez Romero, Alejandra, Goodman, Karyn A., Marks, Lawrence B., Kavanagh, Brian, and Dawson, Laura A.

Published
2021
Full Text
View/download PDF

40. Head and Neck Tumor Control Probability: Radiation Dose–Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group

Author

Vargo, John A., Moiseenko, Vitali, Grimm, Jimm, Caudell, Jimmy, Clump, David A., Yorke, Ellen, Xue, Jinyu, Vinogradskiy, Yevgeniy, Moros, Eduardo G., Mavroidis, Panayiotis, Jain, Sheena, El Naqa, Issam, Marks, Lawrence B., and Heron, Dwight E.

Published
2021
Full Text
View/download PDF

44. The report of Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management

Author

Huq, M Saiful, Fraass, Benedick A, Dunscombe, Peter B, Gibbons, John P, Ibbott, Geoffrey S, Mundt, Arno J, Mutic, Sasa, Palta, Jatinder R, Rath, Frank, Thomadsen, Bruce R, Williamson, Jeffrey F, and Yorke, Ellen D

Subjects
Medical and Biological Physics, Physical Sciences, Cancer, Patient Safety, Humans, Medical Errors, Neoplasms, Quality Assurance, Health Care, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated, Risk Assessment, process mapping, FMEA, FTA, risk-based-QM program, Other Physical Sciences, Biomedical Engineering, Oncology and Carcinogenesis, Nuclear Medicine & Medical Imaging, Biomedical engineering, Medical and biological physics
Abstract

The increasing complexity of modern radiation therapy planning and delivery challenges traditional prescriptive quality management (QM) methods, such as many of those included in guidelines published by organizations such as the AAPM, ASTRO, ACR, ESTRO, and IAEA. These prescriptive guidelines have traditionally focused on monitoring all aspects of the functional performance of radiotherapy (RT) equipment by comparing parameters against tolerances set at strict but achievable values. Many errors that occur in radiation oncology are not due to failures in devices and software; rather they are failures in workflow and process. A systematic understanding of the likelihood and clinical impact of possible failures throughout a course of radiotherapy is needed to direct limit QM resources efficiently to produce maximum safety and quality of patient care. Task Group 100 of the AAPM has taken a broad view of these issues and has developed a framework for designing QM activities, based on estimates of the probability of identified failures and their clinical outcome through the RT planning and delivery process. The Task Group has chosen a specific radiotherapy process required for "intensity modulated radiation therapy (IMRT)" as a case study. The goal of this work is to apply modern risk-based analysis techniques to this complex RT process in order to demonstrate to the RT community that such techniques may help identify more effective and efficient ways to enhance the safety and quality of our treatment processes. The task group generated by consensus an example quality management program strategy for the IMRT process performed at the institution of one of the authors. This report describes the methodology and nomenclature developed, presents the process maps, FMEAs, fault trees, and QM programs developed, and makes suggestions on how this information could be used in the clinic. The development and implementation of risk-assessment techniques will make radiation therapy safer and more efficient.

Published
2016

45. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord

Author

Grimm, Jimm, Sahgal, Arjun, Soltys, Scott G, Luxton, Gary, Patel, Ashish, Herbert, Scott, Xue, Jinyu, Ma, Lijun, Yorke, Ellen, Adler, John R, and Gibbs, Iris C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Prevention, Vaccine Related, Physical Injury - Accidents and Adverse Effects, Neurodegenerative, Traumatic Head and Spine Injury, Spinal Cord Injury, Neurosciences, Humans, Radiation Injuries, Radiation Tolerance, Radiosurgery, Radiotherapy Dosage, Risk, Spinal Cord, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

A literature review of more than 200 stereotactic body radiation therapy spine articles from the past 20 years found only a single article that provided dose-volume data and outcomes for each spinal cord of a clinical dataset: the Gibbs 2007 article (Gibbs et al, 2007(1)), which essentially contains the first 100 stereotactic body radiation therapy (SBRT) spine treatments from Stanford University Medical Center. The dataset is modeled and compared in detail to the rest of the literature review, which found 59 dose tolerance limits for the spinal cord in 1-5 fractions. We partitioned these limits into a unified format of high-risk and low-risk dose tolerance limits. To estimate the corresponding risk level of each limit we used the Gibbs 2007 clinical spinal cord dose-volume data for 102 spinal metastases in 74 patients treated by spinal radiosurgery. In all, 50 of the patients were previously irradiated to a median dose of 40Gy in 2-3Gy fractions and 3 patients developed treatment-related myelopathy. These dose-volume data were digitized into the dose-volume histogram (DVH) Evaluator software tool where parameters of the probit dose-response model were fitted using the maximum likelihood approach (Jackson et al, 1995(3)). Based on this limited dataset, for de novo cases the unified low-risk dose tolerance limits yielded an estimated risk of spinal cord injury of ≤1% in 1-5 fractions, and the high-risk limits yielded an estimated risk of ≤3%. The QUANTEC Dmax limits of 13Gy in a single fraction and 20Gy in 3 fractions had less than 1% risk estimated from this dataset, so we consider these among the low-risk limits. In the previously irradiated cohort, the estimated risk levels for 10 and 14Gy maximum cord dose limits in 5 fractions are 0.4% and 0.6%, respectively. Longer follow-up and more patients are required to improve the risk estimates and provide more complete validation.

Published
2016

47. A User's Guide and Summary of Pediatric Normal Tissue Effects in the Clinic (PENTEC): Radiation Dose-Volume Response for Adverse Effects After Childhood Cancer Therapy and Future Directions

Author

Constine, Louis S., primary, Marks, Lawrence B., additional, Milano, Michael T., additional, Ronckers, Cécile M., additional, Jackson, Andrew, additional, Hudson, Melissa M., additional, Marcus, Karen J., additional, Hodgson, David C., additional, Hua, Chia-Ho, additional, Howell, Rebecca M., additional, Marples, Brian, additional, Yorke, Ellen, additional, Olch, Arthur, additional, and Bentzen, Soren M., additional

Published
2023
Full Text
View/download PDF

48. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting

Author

Gill, Ritu R., Tsao, Anne S., Kindler, Hedy L., Richards, William G, Armato, Samuel G., III, Francis, Roslyn J., Gomez, Daniel R., Dahlberg, Suzanne, Rimner, Andreas, Simone, Charles B., II, de Perrot, Marc, Blumenthal, Gideon, Adjei, Alex A., Bueno, Raphael, Harpole, David H., Jr., Hesdorffer, Mary, Hirsch, Fred R., Pass, Harvey I., Yorke, Ellen, Rosenzweig, Kenneth, Burt, Bryan, Fennell, Dean A., Lindwasser, Wolf, Malik, Shakun, Peikert, Tobias, Mansfield, Aaron S., Salgia, Ravi, Yang, Haining, Rusch, Valerie W., and Nowak, Anna K.

Published
2019
Full Text
View/download PDF

49. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Author

Gomez, Daniel R., Rimner, Andreas, Simone, Charles B., II, Cho, B.C. John, de Perrot, Marc, Adjei, Alex A., Bueno, Raphael, Gill, Ritu R., Harpole, David H., Jr., Hesdorffer, Mary, Hirsch, Fred R., Jackson, Andrew A., Pass, Harvey I., Rice, David C., Rusch, Valerie W., Tsao, Anne S., Yorke, Ellen, and Rosenzweig, Kenneth

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results